Online Inquiry
Get a Quote

Spatial Omics Solutions for Toxicology Research

A treatment-associated response may begin in a small anatomical compartment long before it becomes clear in whole-tissue measurements—or remain restricted to a lesion that is diluted in an organ-level average. Spatial omics helps locate these responses, distinguish affected from relatively preserved regions, and connect histopathology with localized RNA, protein, metabolite, or compound-related signals across dose and time. CD Genomics designs exploratory spatial toxicology studies around the target organ, species or model, tissue format, pathology observations, treatment groups, and mechanism question. By integrating spatial measurements with suitable controls and biological replication, the study can help identify responsive compartments, characterize early or persistent molecular changes, prioritize mechanism hypotheses, and guide focused validation in the next stage of research.

Localized Tissue Response
Dose–Time and Compartment Comparisons
Pathology-Aligned Multi-Omics Evidence
Discuss Your Toxicology Study

Why Toxicology Questions Often Require a Spatial Readout

A tissue-level average can show that a molecular program changed, while histopathology can show where morphology changed. Spatial omics links these observations so that a research team can test whether a response is focal, zonated, compartment-specific, or associated with a particular cell neighborhood.

1

Whole-organ averages dilute focal responses

A small lesion, vascular niche, portal zone, nephron segment, or inflammatory focus may carry a strong response that becomes weak or invisible after homogenization.

2

Morphology alone cannot resolve molecular sequence

Histology can localize structural change, but it does not by itself determine whether stress, metabolic alteration, immune recruitment, cell death, and repair occur in the same region or at the same time.

3

Dissociation removes the anatomical coordinate system

Single-cell or single-nucleus profiling can identify responsive cell states, but spatial evidence is needed to place those states back into tissue zones, lesion boundaries, and neighboring cell communities.

When spatial profiling adds value: the study decision depends on where a response occurs, which anatomical unit carries it, whether it precedes visible injury, or how molecular change aligns with compound or metabolite distribution. If location is not part of the question, a non-spatial assay may be more efficient.

What Can Spatial Toxicology Help You Decide?

Start with the decision the study must support, then select the tissue allocation, biological contrasts, spatial resolution, molecular modality, and validation plan. This keeps the project focused on interpretable evidence rather than a predetermined assay bundle.

Locate

Where is the response?

Determine whether a molecular change is organ-wide, zonated, lesion-restricted, vessel-associated, or concentrated in a specific functional compartment.

Useful evidence: morphology registration, spatial domains, region-level contrasts, and distance-to-lesion analysis.

Attribute

Which cells carry it?

Resolve responsive parenchymal, vascular, stromal, and immune cell states without losing their tissue context.

Useful evidence: cell-type mapping, cell-state scores, neighborhood composition, and targeted in situ confirmation.

Order

When does it appear?

Compare dose and time groups to separate early molecular perturbation from later injury, inflammation, and tissue repair.

Useful evidence: pre-defined contrasts, response trajectories, lesion-grade overlays, and animal-level replication.

Prioritize

What should be validated?

Rank pathways, cell states, metabolites, and candidate markers by spatial agreement, reproducibility, and relevance to the observed tissue phenotype.

Useful evidence: cross-modal concordance, effect-size summaries, targeted panels, and orthogonal assays.

Build a Study Design for Clear Dose, Time, and Tissue Comparisons

Toxicology data are easiest to interpret when the biological unit, treatment contrast, tissue region, and analysis endpoint are planned together. Spots, cells, or multiple sections from one animal are related measurements—not independent animals—so biological replication and region selection must be defined before profiling.

1. Define the Research Contrast

Specify vehicle or control, dose groups, exposure duration, recovery groups, sex or model factors, and the primary comparison before profiling begins.

2. Choose the Biological Replicate

Treat the animal, donor, organoid batch, or independently exposed model as the biological unit. Spots, cells, regions, and serial sections from one unit are related measurements.

3. Anchor Sampling to Tissue Biology

Plan target organ, section level, lesion grade, unaffected comparator region, and serial-section allocation with pathology input.

4. Match Resolution to the Unknown

Use whole-section discovery for unknown domains, region-based profiling for predefined compartments, or single-cell in situ assays for localized cell-state hypotheses.

5. Predefine Evidence Thresholds

Decide which findings require consistency across animals, alignment with morphology, dose or time ordering, cross-modal support, or targeted follow-up.

Spatial toxicology study design linking dose, time, organ, region, and analysis endpoints
Plan the biological contrasts and tissue coordinate system before choosing a spatial platform.
Research Interpretation Note: An early spatial molecular response is a research observation, not proof of an adverse outcome or prediction of human risk. Translational meaning depends on the model, exposure context, pathology findings, and independent validation.

Study Routes for Different Toxicology Questions

These routes are starting points, not fixed packages. A project may use one route or combine selected elements after feasibility review.

Localized Tissue Injury

For a visible lesion whose regional molecular context is unclear
Included Evidence

Pathology-led annotation, whole-section or ROI profiling, lesion-distance comparisons, and a candidate pathway shortlist.

Evidence Boundary

Spatial association does not establish causal injury mechanism or cross-model translation.

Dose–Time Response

For determining when a tissue response appears and whether it persists
Included Evidence

Control, dose, time, and recovery contrasts; animal-level statistics; response ordering; and an early-versus-late evidence matrix.

Evidence Boundary

Temporal ordering alone does not prove adversity or a causal pathway.

Distribution–Mechanism

For examining spatial exposure and tissue response in one anatomical framework
Included Evidence

Spatial metabolite or protein mapping, section registration, regional pathway analysis, and cross-modal concordance review.

Evidence Boundary

Co-localization does not by itself demonstrate target engagement or causality.

Targeted Verification

For testing a discovery shortlist across more units, regions, or archived sections
Included Evidence

A focused RNA or protein panel, cell- or ROI-level quantification, predefined regions, and reproducibility review.

Evidence Boundary

The route tests selected candidates and does not repeat unbiased discovery.

Not sure which route fits? Start with the organ, model, tissue format, dose and time groups, visible pathology, and the decision the study must support. Platform selection follows from those inputs.

Select Each Technology for a Defined Role

No platform is universally best for toxicology. The most useful design assigns each method a specific job and preserves enough tissue for confirmation when the discovery result is known.

Research needTechnology roleBest-fit useDesign considerationsRelated service
Discover tissue-wide response programs Sequencing-based spatial transcriptomics Unknown domains, organ zonation, lesion gradients, and broad pathway discovery Match tissue format, capture area, species compatibility, resolution, and deconvolution plan Spatial Transcriptomics Services
Resolve selected genes at cell or subcellular scale Targeted in situ spatial RNA Confirming cell states, rare populations, and boundary-specific expression Panel content must follow the hypothesis; segmentation and tissue autofluorescence require QC 10x Xenium Spatial RNA Analysis
Compare pathology-defined regions ROI-based spatial RNA or protein profiling Lesion versus adjacent tissue, compartment contrasts, and FFPE archives ROI selection must be reproducible and sufficiently represented across biological units NanoString GeoMx DSP Spatial Proteomics
Map drug, metabolite, or lipid distributions Mass spectrometry imaging and spatial metabolomics Distribution-response overlays, metabolic zonation, and localized biochemical change Analyte annotation, ion suppression, section matching, and tissue chemistry affect interpretation Spatial Metabolomics Services
Characterize cell states for spatial mapping Single-cell or single-nucleus RNA sequencing Reference atlases, rare cell states, and deconvolution support Dissociation or nuclei isolation changes the observable biology and does not preserve location Single-Cell + Spatial Integration
Practical combination: broad spatial discovery can identify the organ zones and pathways that differ; single-cell or single-nucleus data can refine cell-state attribution; targeted spatial RNA, protein, or metabolite measurements can then test a smaller set of prioritized hypotheses.

What You Receive from a Spatial Toxicology Study

A useful report connects data quality, tissue morphology, biological contrasts, and the next research action. Each conclusion should state whether it is directly measured, computationally inferred, or recommended for follow-up.

QC and Exclusion Map

Tissue coverage, read or count quality, segmentation or ROI metrics, folds, tears, necrosis, low-cellularity regions, and excluded areas.

Lesion–Molecular Registration

Spatial domains, pathway scores, or analyte distributions aligned with H&E, IF, pathology regions, and lesion boundaries.

Dose–Time Response Matrix

Animal-level effect sizes and spatial patterns across control, dose, time, and recovery groups without treating spots or cells as independent animals.

Cell-State and Neighborhood Map

Responsive cell states, anatomical niches, cell composition, proximity relationships, and carefully labeled communication hypotheses.

Cross-Modal Evidence Table

RNA, protein, metabolite, and morphology findings compared for concordance, disagreement, missing evidence, and technical limitations.

Follow-Up Shortlist

Prioritized targets, pathways, cell states, or regions with rationale for targeted panels, orthogonal assays, or an expanded cohort.

Example spatial toxicology outputs including lesion overlay, dose-time matrix, cell-state map, and metabolite distribution
Illustrative output types; final plots depend on the study design, tissue, assay, and data quality.
Evidence grading: Reports distinguish measured image, transcript, protein, or metabolite signals from inferred deconvolution, pathway, neighborhood, or communication results, and identify candidates that still require orthogonal or independent validation.

Why Choose CD Genomics for Spatial Toxicology

A toxicology project may need different molecular layers at different stages. CD Genomics supports study design, tissue-compatible platform selection, spatial and single-cell workflows, and customized analysis within one research framework.

Question-Led Study Design

Start with the organ, model, biological contrast, lesion pattern, and decision—not a predetermined platform bundle.

Multi-Modal Evidence Planning

Combine spatial transcriptomics, proteomics, metabolomics, and single-cell references only where each layer has a defined analytical role.

Complex Tissue Feasibility Review

Evaluate FFPE and fresh-frozen material, tissue integrity, species compatibility, capture geometry, and section allocation before assay selection.

Evidence-Aware Analysis

Separate measured observations from computational inference and document QC, exclusions, limitations, and suggested follow-up.

Related routes include Spatial Omics for Pathology, Spatial Omics for Drug Discovery, Spatial Omics for Liver Disease, and Tissue Mapping Services.

Published Research Examples

These peer-reviewed studies illustrate how spatial methods have been applied to drug perturbation and tissue toxicity research. The summaries focus on study design, spatial evidence, and transferable research value.

Drug Perturbation Revealed Spatially Heterogeneous Renal Responses

Onoda et al. DNA Research. 2022. doi:10.1093/dnares/dsac007

Background

The kidney contains closely organized functional compartments, making whole-tissue measurements difficult to attribute to specific renal structures or minor cell populations.

Study Design

Researchers integrated spatial transcriptomics with single-cell RNA sequencing in rat kidney and compared control tissue with tissue collected after losartan administration.

Key Findings

The study localized renin-pathway responses to relevant renal cell populations and reported heterogeneity in the response among glomeruli.

Research Value

The work shows how cell-type references and tissue coordinates can reveal a localized drug response that would be harder to interpret from an organ-average profile.

Boundary

The findings describe a rat-kidney drug-perturbation model and should not be interpreted as proof of human toxicity or clinical risk.

Conceptual rat kidney map showing spatially heterogeneous gene responses after losartan treatment
Original conceptual summary based on Onoda et al. (2022), not a reproduction of a published figure.

Spatial Metabolomics Mapped Zonal Sunitinib-Associated Hepatotoxicity

Zhao et al. Theranostics. 2024. doi:10.7150/thno.99926

Background

Drug-associated liver injury can vary across hepatic zones, cell types, and exposure contexts, which limits interpretation from non-spatial metabolite measurements.

Study Design

The investigators combined spatial metabolomics with histology, immunofluorescence, ultrastructural observations, and targeted cell isolation in a mouse sunitinib model.

Key Findings

The study reported heterogeneous sunitinib distribution and tissue injury involving hepatocytes, bile duct cells, and liver sinusoidal endothelial cells around the portal region.

Research Value

The work illustrates how spatial chemical distribution and tissue phenotype can be examined together to generate a more localized mechanism hypothesis.

Boundary

Spatial co-localization of a compound-related signal and tissue injury supports a localized hypothesis but does not by itself establish target engagement or cross-species translation.

Conceptual liver lobule map showing zonal drug distribution and tissue injury around the portal region
Original conceptual summary based on Zhao et al. (2024), not a reproduction of a published figure.

Frequently Asked Questions

Spatial omics can characterize tissue-associated molecular responses in the studied model and generate hypotheses about localized mechanisms. It does not by itself establish adversity, causality, human translation, or individual risk.

Common target organs include liver, kidney, heart, brain, lung, gastrointestinal tract, and skin, but feasibility depends on species, tissue format, section size, morphology, analyte quality, and the platform required for the research question.

No. A study may investigate a known lesion, a subtle compartment-specific change, or an early molecular response before clear morphology appears. The sampling and interpretation plan should match that objective.

Select groups that test a biological sequence rather than simply maximizing the number of conditions. Include appropriate controls and independent biological units, and preserve enough tissue for pathology review and follow-up assays.

Often, yes. Feasibility depends on fixation, block age, tissue condition, decalcification, section handling, RNA or protein quality, species, and assay compatibility. A feasibility review should precede cohort-scale profiling. See the FFPE Spatial Transcriptomics Service.

Spatial distribution can show where a compound-related ion or metabolite signal is detected, subject to analytical limitations. Target engagement and causal mechanism require appropriate functional or orthogonal evidence.

Provide the organ and species, model, tissue format, number of biological units, control/dose/time groups, pathology findings, available images or annotations, candidate analytes, and the decision the study should support.

Related Spatial Omics Services and Solutions

10x Visium HD

High-resolution, transcriptome-wide spatial discovery for tissue sections.

MALDI-MSI and DESI-MSI

Spatial mapping of metabolites, lipids, and drug-related molecular distributions.

Spatial Data Analysis

QC, spatial domains, differential analysis, cell mapping, and custom interpretation.

Multiparameter Tissue Analysis

Coordinate imaging and molecular evidence across tissue compartments.

References

Onoda N, Kawabata A, Hasegawa K, et al. Spatial and single-cell transcriptome analysis reveals changes in gene expression in response to drug perturbation in rat kidney. DNA Research. 2022;29(2):dsac007. https://doi.org/10.1093/dnares/dsac007

Zhao Q, Lu Y, Duan J, et al. Gut microbiota depletion and FXR inhibition exacerbates zonal hepatotoxicity of sunitinib. Theranostics. 2024;14(18):7219–7240. https://doi.org/10.7150/thno.99926

Plan a Spatial Toxicology Study Around Your Next Decision

Share your organ, model, tissue format, dose and time design, pathology observations, and the mechanism question you need to test. We can help define a feasible spatial workflow and analysis plan.

Discuss Your Study

For research purposes only. Not intended for clinical diagnosis, treatment, or individual health assessment.

Online Inquiry

For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.